Clinical Trial Update: Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer [Phase 1]

View source ↗

Summary

A Phase I trial evaluating the combination of dasatinib and capecitabine in women with advanced breast cancer has completed and posted results in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Sprycel (dasatinib)
• Xeloda (capecitabine)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2013-12-06